EcoSynthetix Reports 2025 First Quarter Results
Highlights
(Comparison periods in each case are the three months ended
- Recorded net sales of
$4.0 million , down 14%, primarily due to an inventory buildup by a distributor in the prior period and an uncertain macro environment. - Recorded an Adjusted EBITDA1 loss of
$0.5 million , relatively unchanged from the prior period. - Won a new commercial line using the Company's SurfLock™ strength aids with a leading international pulp manufacturer.
- Won a new commercial tissue line at an existing customer, the first to originally implement SurfLock™ strength aids who are now using SurfLock™ broadly across their network, demonstrating its value in the tissue, paperboard and pulp end market
- Purchased and cancelled 106,400 common shares in Q1 2025, under the normal course issuer bid for total consideration of
$0.3 million . - Maintained a strong balance sheet with cash and term deposits of
$31.4 million as atMarch 31, 2025 .
"The team continues to execute on our commercial strategy in the key end markets of tissue, pulp, and paperboard, wood composites, and personal care. However, demand during the quarter was supressed on a sequential basis across each of these end markets due to an uncertain macro environment," said
Financial Summary
Net sales were
Gross Profit
Gross profit was
Gross profit as a percentage of sales was 21.5% for Q1 2025, compared to 24.2% in the corresponding period in 2024. Gross profit as a percentage of sales adjusted for manufacturing depreciation was 27.2% for Q1 2025, compared to 29.2% for the corresponding period in 2024. The change in both metrics was primarily due to a lower average selling price.
Selling, General and Administrative
Selling, general and administrative expenses (SG&A) were
Research and Development
Research and development (R&D) costs were
Adjusted EBITDA1
Adjusted EBITDA was
Net Loss
Net loss was
Liquidity
Cash on hand and term deposits were
Notice of Conference Call
1 Non-IFRS Financial Measures
This press release makes reference to certain non-IFRS measures. These non-IFRS measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing a further understanding of results of operations of
Adjusted EBITDA is not a measure recognized under IFRS and does not have a standardized meaning prescribed by IFRS. See "IFRS and Non-IFRS Measures." The Company presents Adjusted EBITDA because the Company believes it facilitates investors' use of operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures (affecting relative interest expense), the book amortization of intangibles (affecting relative amortization expense) and the age and book value of property and equipment (affecting relative depreciation expense). The Company also presents Adjusted EBITDA because it believes it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. Adjusted EBITDA as presented herein are not recognized measures under IFRS and should not be considered as an alternative to operating income or net income as measures of operating results or an alternative to cash flows as measures of liquidity. Adjusted EBITDA is defined as consolidated net income (loss) before net interest expense, income taxes, depreciation, amortization, gain or loss on disposals of property, plant and equipment and other non-cash expenses and charges deducted in determining consolidated net income (loss).
The following table reconciles net loss to Adjusted EBITDA loss for the three months ended
|
Three months ended |
Three months ended |
Net loss |
(606 526) |
(619 346) |
Depreciation |
270 403 |
304 199 |
Share-based compensation |
204 662 |
202 379 |
Interest income |
(369 550) |
(417 049) |
Adjusted EBITDA (loss) |
(501 011) |
(529 817) |
About
Forward-Looking Statements
Certain statements in this Press Release constitute "forward-looking" statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of the Company, or industry results, to be materially different from any future results, performance, objectives or achievements expressed or implied by such forward looking statements. The forward-looking statements in this Press Release include, but are not limited to, statements regarding the Company's plans to execute its commercial strategy, deliver meaningful growth across all three product categories, convert high-value strategic prospects into customers, and other statements regarding the Company's plans and expectations in 2025. These statements reflect our current views regarding future events and operating performance and are based on information currently available to us, and speak only as of the date of this Press Release. These forward-looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such performance or results will be achieved. Those assumptions and risks include, but are not limited to, the Company's ability to successfully allocate capital as needed and to develop new products, as well as the fact that our results of operations and business outlook are subject to significant risk, volatility and uncertainty. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including the factors identified in the "Risk Factors" section of the Company's Annual Information Form dated
EcoSynthetix Inc. |
|
|
Consolidated Balance Sheets |
|
|
(expressed in US dollars) |
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
Current assets |
|
|
Cash |
6 756 790 |
7 721 403 |
Term deposits |
24 676 266 |
24 473 985 |
Accounts receivable |
2 362 743 |
2 325 369 |
Inventory |
3 458 615 |
2 828 748 |
Prepaid expenses |
103 089 |
90 306 |
|
37 357 503 |
37 439 811 |
|
|
|
Non-current assets |
|
|
Property, plant and equipment |
3 655 542 |
3 845 010 |
|
|
|
|
|
|
Total assets |
41 013 045 |
41 284 821 |
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
Current liabilities |
|
|
Trade accounts payables and accrued liabilities |
2 359 523 |
1 938 831 |
Shareholders' Equity |
|
|
Common shares |
489 105 407 |
489 246 909 |
Contributed surplus |
11 068 864 |
11 013 304 |
Accumulated deficit |
(461 520 749) |
(460 914 223) |
Total shareholders' equity |
38 653 522 |
39 345 990 |
|
|
|
Total liabilities and shareholders' equity |
41 013 045 |
41 284 821 |
|
|
|
|
|
|
|
|
|
|
|
|
EcoSynthetix Inc. |
|
|
Consolidated Statements of Operations and Comprehensive Loss |
||
For the three months ended |
|
|
(expressed in US dollars) |
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
2025 |
2024 |
|
|
|
Net sales |
4 042 161 |
4 685 819 |
|
|
|
Cost of sales |
3 174 122 |
3 550 929 |
|
|
|
Gross profit on sales |
868 039 |
1 134 890 |
|
|
|
Expenses |
|
|
Selling, general and administrative |
1 459 547 |
1 722 468 |
Research and development |
384 568 |
448 817 |
|
1 844 115 |
2 171 285 |
|
|
|
Loss from operations |
(976 076) |
(1 036 395) |
|
|
|
Net interest income |
369 550 |
417 049 |
Net loss and comprehensive loss |
(606 526) |
(619 346) |
|
|
|
Basic and diluted loss per common share |
(0,01) |
(0,01) |
Weighted average number of common shares outstanding |
58 531 759 |
58 613 145 |
|
|
|
|
|
|
|
|
|
|
|
|
EcoSynthetix Inc. |
|
|
Consolidated Statements of Cash Flows |
|
|
For the three months ended |
|
|
(expressed in US dollars) |
|
|
|
|
|
|
|
|
|
Three months ended |
|
|
2025 |
2024 |
Cash provided by (used in) |
|
|
|
|
|
Operating activities |
|
|
Net loss and comprehensive loss |
(606 526) |
(619 346) |
Items not affecting cash |
|
|
Depreciation |
270 403 |
304 199 |
Share-based compensation |
204 662 |
202 379 |
Other |
(34 882) |
(13 083) |
Changes in non-cash working capital |
|
|
Accounts receivable |
(37 374) |
(507 258) |
Inventory |
(634 768) |
894 268 |
Prepaid expenses |
(12 783) |
(783) |
Trade accounts payables and accrued liabilities |
445 088 |
926 920 |
Interest on term deposits |
|
|
Interest received on term deposits |
841 794 |
260 450 |
Accrued interest on term deposits |
(314 075) |
(382 650) |
|
121 539 |
1 065 096 |
|
|
|
Investing activities |
|
|
Purchase of property, plant and equipment |
(23 165) |
(152 386) |
Receipts on matured term deposits |
16 550 000 |
12 600 000 |
Purchase of term deposits |
(17 280 000) |
(12 800 000) |
|
(753 165) |
(352 386) |
|
|
|
Financing activities |
|
|
Payments made on lease liability |
(79 442) |
(79 885) |
Common shares repurchased |
(333 842) |
(561 379) |
Exercise of common share options |
43 238 |
44 961 |
|
(370 046) |
(596 303) |
|
|
|
|
|
|
Effect of exchange rate changes on cash |
37 059 |
2 321 |
|
|
|
Change in cash during the period |
(964 613) |
118 728 |
|
|
|
Cash - Beginning of period |
7 721 403 |
4 915 445 |
|
|
|
Cash - End of period |
6 756 790 |
5 034 173 |
SOURCE